Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study

In this article, researchers evaluate the treatment regimens and overall survival outcomes among metastatic bladder cancer (mBC) patients in routine community oncology practice in the USA. Bladder cancer (BC) accounts for approximately 5% of all cancers in the USA. Most BC patients are initially diagnosed with localized or regional tumors that can be treated with local therapy.Cisplatin-based combination chemotherapy, specifically cisplatin + gemcitabine or the dose-dense methotrexate + vinblastine + doxorubicin + cisplatin (MVAC) regimen plus granulocyte colony-stimulating factor, are the regimens recommended by the National Comprehensive Cancer Network (NCCN; PA, USA) guidelines for first-line therapy in the metastatic setting.Gemcitabine...